The eternal dichotomy between early biologic therapy and early surgery in Crohn’s disease: which should truly take precedence?
- 18 October 2025
- journal article
- Published by Taylor & Francis in Expert Review of Gastroenterology & Hepatology
- Vol. 19 (11) , 1149-1152
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Crohn's diseaseThe Lancet, 2024
- A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trialThe Lancet Gastroenterology & Hepatology, 2024
- Adalimumab in Biologic-naïve Patients With Crohn’s Disease After Resolution of an Intra-abdominal Abscess: A Prospective Study From the GETAIDClinical Gastroenterology and Hepatology, 2023
- Breaking Through the Therapeutic Ceiling: What Will It Take?Gastroenterology, 2022
- Surgical management of Crohn’s disease: a state of the art reviewInternational Journal of Colorectal Disease, 2021
- Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: retrospective long-term follow-up of the LIR!C trialThe Lancet Gastroenterology & Hepatology, 2020
- Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: a randomised controlled, open-label, multicentre trialThe Lancet Gastroenterology & Hepatology, 2017
- Practical Approaches to “Top–Down” Therapies for Crohn’s DiseaseCurrent Gastroenterology Reports, 2016
- Cost-effectiveness analysis of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn’s diseaseThe European Journal of Health Economics, 2012
- Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trialThe Lancet, 2008